Cardiff Oncology, Inc. (NASDAQ:CRDF) Stock Has Average Price Target of $7.50

Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) have earned a consensus recommendation of “Hold” from the seven analysts that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and three have given a buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $7.50.

CRDF has been the subject of a number of recent research reports. HC Wainwright upgraded Cardiff Oncology from a “neutral” rating to a “buy” rating in a research report on Tuesday, September 15th. Weiss Ratings upgraded shares of Cardiff Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday. Wall Street Zen raised shares of Cardiff Oncology from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 5th. Finally, William Blair downgraded shares of Cardiff Oncology from an “outperform” rating to a “market perform” rating in a research note on Tuesday, August 11th.

Cardiff Oncology Price Performance

NASDAQ CRDF traded down $0.03 during trading hours on Tuesday, reaching $1.01. 82,495 shares of the stock traded hands, compared to its average volume of 1,096,817. The stock has a 50 day simple moving average of $1.09 and a two-hundred day simple moving average of $1.32. Cardiff Oncology has a 1 year low of $0.76 and a 1 year high of $3.31. The company has a market cap of $78.57 million, a price-to-earnings ratio of -1.68 and a beta of 1.42.

Cardiff Oncology (NASDAQ:CRDF) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). The firm had revenue of $0.10 million during the quarter, compared to analysts’ expectations of $0.06 million. Cardiff Oncology had a negative return on equity of 103.10% and a negative net margin of 7,885.43%. On average, sell-side analysts forecast that Cardiff Oncology will post -0.60 EPS for the current fiscal year.

Hedge Funds Weigh In On Cardiff Oncology

Institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. purchased a new position in Cardiff Oncology in the 2nd quarter worth $1,265,000. GoalVest Advisory LLC purchased a new stake in Cardiff Oncology during the third quarter valued at about $832,000. Flputnam Investment Management Co. purchased a new stake in Cardiff Oncology during the second quarter valued at about $322,000. X Square Capital LLC bought a new position in shares of Cardiff Oncology during the second quarter valued at about $267,000. Finally, GSA Capital Partners LLP bought a new position in shares of Cardiff Oncology during the second quarter valued at about $225,000. Institutional investors own 16.29% of the company’s stock.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biotechnology company focused on developing cancer therapies designed to target difficult-to-treat tumors. The company’s lead investigational product is onvansertib, an oral, highly selective inhibitor of polo-like kinase 1 (PLK1), a protein involved in cell division and tumor growth.

Cardiff Oncology has primarily evaluated onvansertib in combination with existing treatments for patients with RAS-mutated metastatic colorectal cancer, including regimens involving chemotherapy and targeted agents.